Galanti G., Moretti A., Lo Nero L.
Energy for Health [9], 2012
Myalgic fatigue (or muscular contracture caused by functional overload) is clinically detected as an unpleasant feeling of one or more muscles, that appears within 24 hours after exercise and disappears in 5-7 days. In athletes, often the muscular contracture is not due to pathological alterations of muscle metabolism, but rather to a condition of lack of training, as typically happens at the beginning of the training season or after a period of enforced rest due to trauma or injury. Laser therapy has long been widely used to treat muscle pain and contracture, and recently it has also been proposed to prevent injuries from overwork in athletes. The aim of this study was to evaluate the efficacy of an advanced IR laser system, the MLS laser, in combination with the other components of standard therapy for the treatment of muscular contracture. MLS system is a laser device with special characteristics: it is equipped with synchronized combination of continuous and pulsed emissions. The first one (that may emit also in pulsed mode) with λ=808 nm and maximum power of 1W, the other one with λ=905 nm and peak power of 25W. Here we report the case of a 16 years old athlete in good health state and with no previous muscle injury. The athlete reported a rectus femoris pain after a work of multiple running on 200 meters. After 3 days of MLS treatment, associated with mobilization of the muscle, stretching and eccentric contraction exercise, the athlete reported negative clinical examination for pain and muscle contracture and was available to work with the team. Studies are in progress to confirm our findings increasing the number of cases and also evaluating the efficacy of MLS laser therapy on different types of injury.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.